Figure S2 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy di Laura Boucai (15054310)

Altri autori:

Table S1 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy di Laura Boucai (15054310)

Altri autori:

Table S6 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy di Laura Boucai (15054310)

Altri autori:

Table S2 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy di Laura Boucai (15054310)

Altri autori:

Figure S4 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy di Laura Boucai (15054310)

Altri autori:

Figure S3 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy di Laura Boucai (15054310)

Altri autori:

Table S4 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy di Laura Boucai (15054310)

Altri autori:

Figure S1 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy di Laura Boucai (15054310)

Altri autori:

Table S3 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy di Laura Boucai (15054310)

Altri autori:

Table S5 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy di Laura Boucai (15054310)

Altri autori:

Supplementary Figure from Mutated HRAS Activates YAP1–AXL Signaling to Drive Metastasis of Head and Neck Cancer di Sankar Jagadeeshan (15112900)

Altri autori: